Related Experiment Video

Updated: Jul 18, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Integration of pediatric aspects into the general drug development process

K Rose1

  • 1F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Basel, Switzerland. klaus.rose@roche.com

Ernst Schering Research Foundation Workshop
|November 23, 2006
PubMed

Insights

Pediatric drug development faces challenges due to limited clinical testing. Legislation in the US has improved pediatric medicine safety and efficacy, with similar approaches considered globally.

Area of Science:

  • Pharmacology
  • Pediatrics
  • Regulatory Science

Background:

  • Pediatric drug treatment often lacks formal clinical testing compared to adults, raising safety and efficacy concerns.
  • Increased awareness of child physiology and evolving societal views on children's rights drive the need for pediatric-specific drug development.
  • Public action in the US and EU has spurred legislative changes to address gaps in pediatric medicine research.

Purpose of the Study:

  • To examine the impact of pediatric legislation on pharmaceutical innovation.
  • To discuss the complexities and requirements for integrating pediatric considerations into drug development.
  • To highlight the need for a shared responsibility framework among stakeholders.

Main Methods:

  • Review of existing pediatric legislation and its outcomes.
  • Analysis of challenges in global pharmaceutical companies developing pediatric medicines.
  • Discussion of ethical and economic considerations in pediatric drug development.

Main Results:

  • US pediatric legislation has successfully facilitated children's participation in pharmaceutical innovation over 8 years.
  • Comparable legislative approaches are under consideration in Europe and Japan.
  • Global pharmaceutical companies face complexity in building internal competency for pediatric drug development.

Conclusions:

  • Effective pediatric drug development requires addressing regulatory, economic, and ethical frameworks.
  • Shared responsibility among regulatory authorities, industry, healthcare providers, and patients is crucial.
  • The success of US legislation provides a model for future pediatric drug development initiatives worldwide.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...